-
Mashup Score: 33
Invasive mucinous adenocarcinoma (IMA) is a type of primary lung adenocarcinoma characterized by tumor cells that exhibit a goblet or columnar cell morphology and contain large amounts of intracytoplasmic mucin. IMA is a relatively rare tumor, accounting for 3-10% of lung adenocarcinomas 1 2 3. Approximately 55% of cases occur in females 3, and there is a tendency for the disease to be more common in non-smokers or light smokers 4 .
Source: www.clinical-lung-cancer.comCategories: General Medicine NewsTweet
-
Mashup Score: 44
Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of PD-(L)1 inhibitors by inhibiting protumor inflammation.
Source: www.jtocrr.orgCategories: General Medicine NewsTweet-
Results from negative phase 2 CANOPY-N trial @JTOonline. Pts with resectable NSCLC randomized to neoadjuvant canakinumab (anti IL-1β), pembrolizumab, or both. Canakinumab MPR 3%, pembro MPR 17%, combo MPR 17%. Disappointing but glad results published. https://t.co/gWZ1wN6IqT
-
-
Mashup Score: 114
The PHAROS primary analysis showed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report results after 18 months of additional follow-up.
Source: www.jto.orgCategories: General Medicine NewsTweet-
Update from the Phase 2 PHAROS Study of encorafenib + binimetinib in #BRAF V600E NSCLC @JTOonline. As 1L therapy, RR 75%, DOR 40m, PFS 30m, 3y OS rate 53%. In previously treated, RR 46%, DOR 16.7m, PFS 9.3m, OS 22.7m, 3y OS 29%. https://t.co/RP8Lq8omsM
-
-
Mashup Score: 9
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard 25 June | 15:30–17:30 CEST/ 08:30–10:30 CDT/ 14:30–16:30 BST Agenda available soon
Source: us06web.zoom.usCategories: General Medicine NewsTweet-
RT @OncoAlert: You're invited to join the Post #ASCO25 #LungCancer 🫁Highlights webinar, Register here👉 https://t.co/MIQP43N0UT ⭐️June 25,…
-
-
Mashup Score: 77
Microabstract: Osimertinib showed PFS of 20.1 months and OS of 42.0 months in EGFRm+ NSCLC, comparable to those of the FLAURA trial. Adverse events included pneumonitis (16.7%), QT prolongation (4.6%), and ejection fraction decrease (2.6%). Events such as pneumonitis (17 cases) and cardiotoxicity (7 cases) were observed after 1 year, underscoring the need for long-term safety monitoring.
Source: www.clinical-lung-cancer.comCategories: General Medicine NewsTweet-
Real world outcomes in Japan with 1L osimertinib monotherapy in #EGFR NSCLC (OSI-FACT-OS) @ClinicalLung. With median f/u of 37m, mPFS 20.1m and mOS 42m. All grade pneumonitis rate 16.7% (G3+ was 5.2%), uncommon after first year on therapy. https://t.co/EqeNVxhbOc
-
-
Mashup Score: 27
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard 25 June | 15:30–17:30 CEST/ 08:30–10:30 CDT/ 14:30–16:30 BST Agenda available soon
Source: us06web.zoom.usCategories: General Medicine NewsTweet-
Join Dr. @NReguart, Dr. @nicogirardcurie and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar with @VJOncology where we discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data! https://t.co/gNBYTZubVa https://t.co/9KoY1bE0ua
-
-
Mashup Score: 37
PURPOSEORCHARD (ClinicalTrials.gov identifier: NCT03944772) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor (EGFR)–…
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Results from osimertinib + necitumumab module of phase II ORCHARD study @JCOPO_ASCO. Pts with #EGFR NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received osi 80mg + neci D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE. https://t.co/ynkrrcMLMp
-
-
Mashup Score: 52
Rearrangements of the lung adenocarcinoma gene creating oncogenic fusions in anaplastic lymphoma kinase (ALK), of which the most common is echinoderm microtubule-associated protein-like 4 (EML4), account for approximately 4 %–8 % of non–small-cell lung cancers (NSCLC).1-4 Brigatinib, an oral tyrosine kinase inhibitor (TKI) approved for the treatment of adults with metastatic ALK-positive NSCLC,5 has potent activity against oncogenic ALK fusions and has demonstrated activity against a broad range of ALK mutations associated with resistance to other TKIs, including crizotinib.
Source: www.clinical-lung-cancer.comCategories: General Medicine NewsTweet-
Brigatinib post crizotinib in #ALK NSCLC @ClinicalLung from @LudaBazhenovaMD. High response rates seen independent of secondary ALK mutations but if alterations seen in non-ALK secondary drivers (EGFR, KRAS, BRAF, MET0, no responses seen. https://t.co/nH95z4y73j
-
-
Mashup Score: 21
Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered non-small cell lung cancers (NSCLCs). Preclinically, type II TKIs like cabozantinib can rescue progression on type I TKIs. This phase 2 trial (NCT01639508) evaluated cabozantinib’s activity in patients with MET-dependent lung cancers, including TKI-pretreated cancers.
Source: www.jtocrr.orgCategories: General Medicine NewsTweet-
Phase II study of cabozantinib in #MET altered lung cancer @JTOonline from @HaradaGuilherme @alexdrilon (n=28). RR 20% and 4/5 responses were previously treated with type I MET TKI. PFS 4.5m, OS 7.2m. https://t.co/aqKl04Jpy5
-
-
Mashup Score: 38ASCO 2025 Highlights | IASLC - 8 day(s) ago
This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe …
Source: www.iaslc.orgCategories: General Medicine NewsTweet-
In this episode of the @IASLC podcast, Lung Cancer Considered, I am joined by Drs. @NarjustFlorezMD @CharuAggarwalMD @FordePatrick to discuss the most impactful lung cancer studies from #ASCO25. Available wherever you download podcasts! https://t.co/dkjpYVIwC0
-
Genomic landscape of resected invasive mucinous adenocarcinoma @ClinicalLung (n=107). KRAS mutations common - in 70.1% of cases - with NRG1 fusions identified in 9.2% of cases. Best identified with RNA seq. https://t.co/1kpVjA9md7